Anabolic androgenic steroid-induced liver injury: An update

Ana Petrovic, Sonja Vukadin, Renata Sikora, Kristina Bojanic, Robert Smolic, Davor Plavec, George Y Wu, Martina Smolic

Specialty type: Gastroenterology and hepatology
Provenance and peer review: Invited article; Externally peer reviewed.
Peer-review model: Single blind
Peer-review report's scientific quality classification
  Grade A (Excellent): 0
  Grade B (Very good): B, B
  Grade C (Good): C
  Grade D (Fair): D
  Grade E (Poor): 0
P-Reviewer: He F, China; Kreisel W, Germany; Liu P, China
Received: January 11, 2022
Peer-review started: January 11, 2022
First decision: March 8, 2022
Revised: March 22, 2022
Accepted: June 18, 2022
Article in press: June 18, 2022
Published online: July 14, 2022

Abstract

Anabolic androgenic steroids (AASs) are a group of molecules including endogenous testosterone and synthetic derivatives that have both androgenic and anabolic effects. These properties make them therapeutically beneficial in medical conditions such as hypogonadism. However, they are commonly bought illegally and misused for their anabolic, skeletal muscle building, and performance-enhancing effects. Supraphysiologic and long-term use of AASs affects all organs, leading to cardiovascular, neurological, endocrine, gastrointestinal, renal, and hematologic disorders. Hepatotoxicity is one of the major concerns regarding
AASs treatment and abuse. Testosterone and its derivatives have been most often shown to induce a specific form of cholestasis, peliosis hepatis, and hepatic benign and malignant tumors. It is currently believed that mechanisms of pathogenesis of these disorders include disturbance of antioxidative factors, upregulation of bile acid synthesis, and induction of hepatocyte hyperplasia. Most toxicity cases are treated with supportive measures and liver function normalizes with discontinuation of AAS. However, some long-term consequences are irreversible. AAS-induced liver injury should be taken in consideration in patients with liver disorders, especially with the increasing unintentional ingestion of supplements containing AAS. In this paper, we review the most current knowledge about AAS-associated adverse effects on the liver, and their clinical presentations, prevalence, and pathophysiological mechanisms.

Key Words: Androgens; Steroids; Cholestasis; Fibrosis; Liver; Chemical and drug induced liver injury

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: There is a great deal of literature on the prevalence, pathophysiology, and therapeutic options for anabolic androgenic steroid (AAS)-associated adverse effects. However, AAS-induced liver injury is perhaps still underreported and poorly understood. In this paper, we review the latest knowledge obtained about molecular mechanisms of AAS-associated liver injury from most recent in vitro and animal studies, as well as the latest case reports regarding adverse effects of AASs in dietary supplements.

Citation: Petrovic A, Vukadin S, Sikora R, Bojanic K, Smolic R, Plavec D, Wu GY, Smolic M. Anabolic androgenic steroid-induced liver injury: An update. World J Gastroenterol 2022; 28(26): 3071-3080

URL: https://www.wjgnet.com/1007-9327/full/v28/i26/3071.htm

DOI: https://dx.doi.org/10.3748/wjg.v28.i26.3071

INTRODUCTION

Anabolic androgenic steroids (AASs) are group of compounds that include endogenous androgens, most importantly testosterone, and their synthetic derivatives[1]. Testosterone and synthetic AASs have been commonly used for their androgenic masculinizing effects resulting in male secondary characteristics, as well as anabolic skeletal muscle building effects due to enhanced protein utilization and synthesis mechanisms[2,3]. AASs are medically indicated in conditions such as male primary and secondary hypogonadism, aplastic anemia, muscle wasting in human immunodeficiency virus-infected patients, osteoporosis, libido dysfunction, chronic kidney disease, and breast cancer[4]. However, they are often misused because of their performance-enhancing and anabolic effects resulting in increased fat-free mass and improved muscle fiber size and strength. Abuse of AASs for aesthetic purposes and athletic performance improvement has surged as a public health problem in the past few decades among both professional and recreational athletes and bodybuilders[5,6]. Unmodified testosterone is rapidly metabolized when administered orally or parenterally and exerts a similar proportion of andabolic and androgenic effects. Chemical modifications of testosterone allow prolonged effective blood concentrations and changes to its pharmacodynamic properties, therefore enhancing desired anabolic or androgenic effects. In its synthetic derivatives used for aesthetic and performance-enhancing purposes, testosterone is altered mainly through alkylation and esterification to enhance bioavailability by reducing hepatic metabolism, prolong duration of action, and maximize anabolic properties, though all of the synthetic compounds still exert significant androgenic effects. Supraphysiologic doses and prolonged unsupervised use of AASs have major impacts on users, affecting all organs and causing cardiovascular, neuroendocrine, neuropsychiatric, renal, gastrointestinal, muscularkeletal, dermatologic, immune, and hematologic disorders. Testosterone has a major impact on homeostasis of electrolytes, macromolecules, and micromolecules, including alterations in systemic iron balance and erythropoiesis. It has been established that AAS-induced erythropoiesis is mediated by erythropoietin[7]. Most recent studies also imply suppression of hepcidin (a negative regulator of the iron transporter ferroportin) as a mechanism of androgen-induced enhanced iron absorption and incorporation into red blood cells[8]. Some of the most common adverse effects related to AASs are dyslipidemia, hypertension, hypogonadism and infertility, aggression and mood disorders, addiction, and liver and kidney injury[9-11]. This has led to stricter laws regarding availability of AASs, mainly in professional sports organizations which ban anabolic steroid use, and test competitors for the presence of illegal steroids not only because of the unfair advantage in performance, but also because of their potentially dangerous side effects. In legal terms, AASs are classified in the United States as schedule 3 drugs by the
HEPATOTOXICITY

Since the 1950s, a significant number of studies and case reports have raised concerns regarding hepatotoxic effects including cholestasis, hepatic neoplasms, hepatocyte toxicity, and peliosis hepatis related to the use of AASs[11,18]. Correlation between steroids and these effects has been attributed to the role of the liver as the primary clearance site for AASs. As mentioned before, synthetic steroids are usually modified to prevent first-pass hepatic metabolism, preventing their clearance by the liver and, therefore, elevating their risk of hepatotoxicity[19]. Most studies of long-term use have not identified exact dosages and concentrations, administration paths, and types of steroid compounds often used simultaneously. Prospective studies with supraphysiologic doses are difficult to gain institutional review board (IRB) approval due to ethical and legal considerations[20], therefore randomized controlled trials are lacking and in this minireview we discuss data from case reports, in vitro studies, and studies on animal models.

Proposed mechanisms of liver injury include anabolic steroid-induced infiltration of inflammatory cells in the hepatic tissue, and Kupffer cell activation resulting in production of inflammatory cytokines and collagen deposition, increased oxidative stress and reactive oxygen species with subsequent mitochondrial degeneration in liver cells, and stimulation of intracellular androgenic steroid receptors inducing unregulated growth of hepatocytes. An in vitro study in 2021 reported that disruption of mitochondrial respiratory chain reactions occurs early in the pathogenesis of liver injury caused by supraphysiologic doses of nandrolone, a synthetic AAS commonly used for performance enhancement. It specifically inhibits respiratory chain complexes I and III, which causes accumulation of reactive oxygen species and oxidative stress[21]. Indeed, earlier animal studies detected a reduced amount of glutathione and enzymes that serve as free radical scavengers (superoxide dismutase and catalase) as well as increasing thiobarbituric acid-reactive substances indicating impaired redox homeostasis[22,23]. Furthermore, oxidative stress interfered with mitochondrial membrane potential dynamics[24] and altogether resulted in reduced cell energy supply leading to malfunction and necrosis of hepatocytes. Apart from disturbance in cellular function, distortion in mitochondrial morphology and increased number of lysosomes in hepatocytes were observed by electron microscopy[25]. Another process observed after prolonged administration of nandrolone in animal studies was excess collagen deposition in liver parenchyma. It is known that AASs induce infiltration of the liver with inflammatory cells, which together with activated Kupffer cells, favor a pro-inflammatory state by releasing nuclear factor-κB (NF-κB) and inflammatory cytokines transforming growth factor β1 (TGF-β1), tumor necrosis factor alpha (TNFα), and interleukin-1B (IL-1B). Such conditions also lead to activation of liver stellate cells, resulting in excessive collagen synthesis and deposition[26]. Interestingly, AASs can also promote collagen synthesis by activating their intracellular receptor and activation of transcription factors involved in collagen synthesis[27]. A recent study also gave convincing evidence for a role of testosterone in the pathophysiology of liver diseases with higher occurrences in males than in females. It demonstrated that the susceptibility of the mouse liver to injury was correlated with excessive inflammatory response mediated by androgen receptors (ARs) and testosterone-induced NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation associated with a variety of chronic diseases[28]. Hepatotoxicity of AASs may also vary due to individual susceptibility, pre-existing liver conditions, and genetic factors. Most frequently reported liver disorders related to AASs are cholestasis, peliosis hepatis, and development of liver tumors[11,29-32]. Figure 1 shows an overview of proposed mechanisms of hepatotoxicity caused by AAS.

AAS drug-induced liver injury (AAS DILI) has also been frequently reported to cause serum liver enzyme elevations in AAS users. Elevated aspartate transaminase (AST), alanine transaminase (ALT), and lactate dehydrogenase (LDH) activities are, in general, regarded as indicators of hepatocellular damage. Transient elevation of AST and ALT in plasma has been largely reported in AAS users [33], but liver damage may not be the cause of the elevations because of the possible contribution of heavy and intense workouts with consequent muscle damage and rhabdomyolysis. Thus, liver enzymes
Figure 1 Proposed mechanisms of anabolic androgen steroid-induced liver injury. A: Oxidative stress in the mitochondria. Anabolic androgenic steroids (AASs) impair mitochondrial respiratory function, which leads to reactive oxygen species (ROS) accumulation. Cell membrane is damaged due to lipid peroxidation and intracellular ATP depletion occurs due to mitochondrial impairment. This results in cellular dysfunction at many levels (e.g., toxic compounds can enter the cell). Mitochondrial morphology is also changed, with reduced cristae and swelling. In addition, there is an increase in lysosome number. Lack of energy supply eventually leads to hepatocyte necrosis. B: Immune cell infiltration of liver parenchyma. Long-term treatment with AASs like nandrolone is associated with immune cell infiltration which maintains proinflammatory state in liver tissue. Under such conditions, Kupffer cells release transforming growth factor beta 1 (TGF-β1), tumor necrosis factor alpha (TNFα), and interleukin-1β (IL-1β) which mediate hepatic stellate cell activation: Extracellular matrix and collagen deposition leading to liver fibrosis; C: Hepatocyte hyperplasia causes formation of hepatic tumors. In rats treated with high-dose nandrolone, it was observed that it supported the viability of hepatic stem cells, which are potential reservoir of cancer stem cells. Nodular hepatocyte hyperplasia causes parenchyma distortion and mechanical blockage of vasculature which forms cystic lesions filled with blood, known as peliosis hepatic; D: “Bland cholestasis”. Activation of androgen receptors (ARs) by AASs interferes with bile transporters, mediates intrahepatic microfilament damage, and increases expression of genes for acid bile and bile transporter synthesis, and these changes result in bile acid accumulation, cholestasis, and cholestatic jaundice. SOD: Superoxide dismutase; CAT: Catalase; AR: Androgen receptor; AAS: Anabolic androgenic steroid; AR: Androgen receptor. Figure created with Servier Medical Art, https://smart.servier.com/.
can be elevated independent of androgenic steroid use. Studies showing elevations of creatine kinase (CK) and AST, with no ALT and gamma glutamyl transferase (GGT) elevations, support this concept and suggest that hepatotoxicity related to AASs may be over-estimated if serum ALT, AST, and GGT concentrations are the sole criteria used[34]. Furthermore, a recent multi-center prospective study regarding the incidence of liver injury in transgender patients treated with hormone therapy including AASs showed no significant ALT, AST, alkaline phosphatase (ALP), or GGT elevations[35]. Most of the hepatotoxic effects, cholestasis, peliosis, and liver tumors are associated with orally administered AASs such as testosterone cypionate, enanthate, propionate, methyltestosterone, oxymethalone, danazol, stanozolol, formebolone, and methandienone[36,37], but intramuscular preparations were also linked to hepatotoxic effects[38]. Patil et al[38] reported three cases of AAS-induced hepatotoxicity which all manifested differently. The first case was a 31-year-old man who developed cholestatic liver injury after 2 mo of oxymetholone use, the second case was a 24-year-old man who developed well-differentiated hepatocellular carcinomas (HCC) and multiple hepatic adenomas after 3 years of intramuscular testosterone decanoate and daily oral stanozolol use, and the third case was a 36-year-old man with steatohepatitis after 2 mo of intramuscular nandrolone decanoate use[38]. The exact incidence of AAS DILI is difficult to establish due to both underreporting and lack of awareness. On the other hand, even when a history of AAS use is known, it may be difficult to establish the causality, particularly when multiple agents are used concomitantly or if there is an underlying liver condition. However, there has been a trend of increased AAS DILI reporting in recent years which may lead to new insights into pathophysiology and disease course. According to currently available data, AAS DILI has a good prognosis as the majority of cases recover completely and only a very small number of cases develop hepatic failure or die[39].

**CHOLESTASIS**

Although treated patients with parenterally administered unmodified testosterone, 17a-alkyl-substituted steroids, which are designed to decrease hepatic metabolism, directly contribute to a highly characteristic form of acute cholestasis, ranging from very mild to severe. Some characteristic clinical manifestations are nausea, pruritus, fatigue, jaundice, and dark urine with elevated bilirubin and ALP, but without significant elevations of AST, ALT, and GGT. Such characteristics are indicative of cholestasis with minimal inflammation of the liver or bile duct. Resolution usually occurs upon discontinuation of anabolic steroids, although some case reports indicate benefits of hydrocortisone and ursodeoxycholic acid treatment[13,39–42].

Some animal model studies have suggested AAS-induced disruption of intrahepatic microfilaments and interference with bile transporter proteins as a pathophysiological mechanism of this syndrome rather than inflammation and injury to the liver and bile duct[29,43]. El-Sherrif et al[13] reported two cases of cholestatic DILI caused by the short-term use of AAS-containing dietary supplement Mass-Drol. The authors found that inhibition of expression of genes ATP8B1 and ABCB11 by AAS may play a crucial role as the underlying mechanism of cholestatic injury. This leads to impaired bile salt transport and also reduced excretion of different hepatic ectoenzymes. Indeed, both patients presented with cholestasis with marked hyperbilirubinemia, but lack of GGT rise. The authors postulated that individuals who are carriers of c.2093G >A mutation in ABCB11 may be specifically susceptible to cholestatic hepatic injury caused by AASs due to this mechanism[13]. Additionally, the role of multidrug-related proteins (MRP2, MRP3, and MRP4) is important in bile acid transfer as a complimentary mechanism. It was shown that testosterone metabolites are substrates of MRP2 protein, which has reduced activity in Dubin-Johnson syndrome (DJS). The effect of AAS in DJS has not been investigated to our knowledge, whereas it was found that pregnancy and oral contraceptives increase bilirubin levels in women with DJS[44]. Different underlying mechanism was proposed by Petrov et al[45], who used an in vitro model to demonstrate that AR activation may upregulate the expression of bile acid synthesis genes as well as bile acid transporters. Most recent studies have reported that the patterns of “bland” cholestasis in AAS users are so specific that this picture can be virtually sufficient to make a diagnosis of AAS-induced cholestasis[46]. Many reports refer to these phenomena as AAS DILI[39,47].

**PELIOSIS HEPATIS**

Peliosis hepatis is a rare condition characterized by hypervascular liver parenchyma and blood-filled cysts that is known to be associated with use of AASs and several other drugs like estrogens, corticosteroids, and azathioprine. So far, disruption of hepatic extracellular matrix and direct endothelial cell injury have been suggested as generating mechanisms for liver peliosis. It has also been proposed that steroid-induced hepatocyte hyperplasia results in mechanical obstruction of hepatic vascular system, causing dilatation and loss of endothelial barrier function[11,30,48]. Molecular mechanisms in pathophysiology of peliosis remain poorly understood; however, an important role of vascular
endothelial growth factor (VEGF) has been suggested in recent studies. VEGF induces angiogenesis, capillary permeability, and proliferation of endothelial cells in liver and other tissues. Tzirogiannis et al [49] found a major protective effect of VEGF which almost totally reversed the extent of peliosis in a model of cadmium-induced toxic liver injury and peliosis, implying that it preserves endothelial cell function. However, a study of peliosis hepatitis in a patient with follicular lymphoma found elevated VEGF and suggested that lesions could be caused by elevation of VEGF and its angiogenic effects[50]. An animal model study of peliosis hepatitis associated with melanoma supports a concept that a tumor-derived factor such as VEGF could induce development of peliosis due to its endothelial cell proliferation effect[51]. These conclusions indicate a need for further research of pathophysiology in peliosis hepatitis as well as AASs and their impact on growth factors. Peliosis hepatitis is commonly asymptomatic, but case reports described presentation characterized by sharp abdominal pain and hemopteritoneum in cases of cyst rupture[52]. Peliosis is usually treated with supportive care and the condition has shown to regress with discontinuation of AASs[53,54]. The condition has been reported not only in use of 17-alpha-alkylated steroids, but also in patients treated with unmodified testosterone[19]. Given its benign nature, most cases of peliosis hepatitis are incidentally found and the most appropriate diagnostic modalities are magnetic resonance imaging[55] and histological examination. Once diagnosed, the offending drug should be discontinued and the condition closely monitored to reduce the risk of rupture, especially with larger lesions.

NEOPLASMS

Hepatic tumors, ranging from benign adenomas to malignant hepatocellular carcinoma, have been reported in patients with long-term anabolic steroid therapy[56-58]. Studies have suggested a higher hepatic cancer prevalence in males than in females. Higher endogenous concentrations of androgens may be a major factor in the development of liver carcinomas. Having both the estrogen and ARs, the liver is a hormone sensitive organ. The use of AASs is highly associated with hepatocyte proliferation and liver tumors[59]. An in vitro study on HepG2 cells showed that a supraphysiologic dose of nandrolone changed their phenotype to be stem-like, but the mechanism of this transformation remains to be elucidated. In the same study, nandrolone administered in vivo in a mouse model promoted “stemness” in healthy organs, primarily ones naturally rich in stem cells such as the liver. Cell “stemness” phenotype is a metabolically latent state in which there is a lower oxygen consumption in the mitochondria. Expression of Nanog, Lin28, Myc, and Klf4 genes and CD133 membrane protein is also considered to be markers of cell stemness. This led to a hypothesis that long-term supraphysiologic doses of nandrolone in young healthy individuals possibly increase the risk of malignancy in stem-cell rich organs by increasing the reservoir of stem cells which over a period of time under additional toxic stimuli may turn into cancer stem cells[21]. Studies to date indicate that most of AAS-induced tumors occur with use of agents containing a 17-alpha-alkyl group, but it has also been reported in patients treated with unmodified testosterone[56,60,61]. Histologically, these tumors are most commonly hepatic adenomas or HCC, but cholangiocarcinomas and angiosarcomas have also been reported with long-term AAS use[20]. Given the possibility of malignant transformation of hepatic adenoma, which occurs 10 times more commonly in men than in women, it is recommended that surgical resection be the most appropriate approach in men. In women, estrogen-containing oral contraceptives are a common cause, so their cessation, together with periodic surveillance, is an acceptable approach[62,63]. Solimini et al[11] reviewed case reports regarding liver tumors as well as cholestatic hepatitis associated with AASs and reported that several different AAS agents were associated with such liver pathology. Notably, chronic AAS use of several years is linked to development of HCC, while benign neoplasms were mostly linked to short-term use of AAS[11].

ADDITIONAL CONCERNS REGARDING AASS AND THE LIVER

Other hepatic disorders associated with AASs include toxicant-associated fatty liver disease (TAFLD), and possible increased risk of hepatitis B and C infections due to unsafe administration of AASs[64]. In addition, a negative effect on lipoproteins with reduced HDL-cholesterol and increased LDL-cholesterol concentrations has been reported mostly in long-term steroid users[65,66], which contribute to increased risk of coronary disease with AAS use.

Another concerning issue is the increasing number of mislabeled over-the-counter dietary supplements sold legally and containing significant amount of AASs. This has also been associated with adverse effects, but remains underreported and poorly understood. However, new case reports have been published on DILI with jaundice, cholestasis, dyslipidemia, and elevated serum liver enzyme panels in patients directly associated with dietary supplement use. After discontinuation of supplements, liver function commonly returned to normal[67,68]. Consumers may unknowingly use AASs which can result in acute, but also chronic, health problems that are difficult to link to these products and lead to re-exposure[69-71].
CONCLUSION

AAS use is closely linked to hepatotoxicity and serious hepatic conditions such as cholestasis, peliosis hepatitis, and benign and malignant hepatic tumors, as well as steatohepatitis and dyslipidemia with multiple studies supporting a causal association. Several pathophysiological mechanisms have been proposed including AR receptor-mediated inflammatory response, disturbance of hepatic antioxidant factors, promotion of hepatocyte hyperplasia, and upregulation of bile acid synthesis. Most of these conditions have been reported with 17-alpha-alkylated steroids. Liver function usually returns to normal with discontinuation of use, but a higher HCC prevalence with AASs is concerning. Another important fact is the increasing number of case reports presenting patients with dietary supplements-associated liver conditions that are still underreported. Given all of the above, screening for liver pathology in known AAS users should be considered in order to possibly reverse the condition. Also, if certain liver pathology is diagnosed incidentally, a history of AAS as potential causal agent should be actively sought, and if found, addressed promptly.

FOOTNOTES

Author contributions: Petrovic A, Smolic R, Smolic M, and Wu GY designed the research study; Petrovic A, Vukadin S, Sikora R, Bojanic K, Plavec D, and Smolic M performed the research; Petrovic A and Vukadin S analyzed the data and wrote the manuscript; all authors have read and approved the final manuscript.

Conflict-of-interest statement: There are no conflicts of interest to report.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Croatia

ORCID number: Ana Petrovic 0000-0001-5585-3121; Sonja Vukadin 0000-0002-1636-2538; Renata Sikora 0000-0001-8594-549X; Kristina Bojanic 0000-0003-4473-5706; Robert Smolic 0000-0003-4614-4344; Davor Plavec 0000-0003-2020-8119; George Y. Wu 0000-0003-0068-1072; Martina Smolic 0000-0002-6867-826X.

S-Editor: Chen YL
L-Editor: Wang TQ
P-Editor: Chen YL

REFERENCES

1 Roman M, Roman DL, Ostafe V, Ciorsac A, Ivoran A. Computational Assessment of Pharmacokinetics and Biological Effects of Some Anabolic and Androgen Steroids. Pharm Res 2018; 35: 41 [PMDID: 29404794 DOI: 10.1007/s11095-018-2353-1]
2 Mullen C, Whalley BJ, Schifano F, Baker JS. Anabolic androgenic steroid abuse in the United Kingdom: An update. Br J Pharmacol 2020, 177: 2180-2198 [PMDID: 31989581 DOI: 10.1111/bph.14945]
3 Barceloux DG. Palmer RB. Anabolic-androgenic steroids. Dis Mon 2013; 59: 226-248 [PMDID: 23719201 DOI: 10.1016/j.disamonth.2013.03.010]
4 Margo K, Winn R. Testosterone treatments: why, when, and how? Am Fam Physician 2006; 73: 1591-1598 [PMDID: 16719252]
5 Basaria S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab 2010; 95: 1533-1543 [PMDID: 20139230 DOI: 10.1210/jc.2009-1579]
6 Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996, 335: 1-7 [PMID: 8637535 DOI: 10.1056/NEJM199607043350101]
7 Shahidi NT. Androgens and erythropoiesis. N Engl J Med 1973; 289: 72-80 [PMDID: 4575719 DOI: 10.1056/NEJM197307012280920]
8 Beggs LA, Yarrow JF, Conover CF, Meuleman JR, Beck DT, Morrow M, Zou B, Shuster JJ, Borst SE. Testosterone alters iron metabolism and stimulates red blood cell production independently of dihydrotestosterone. Am J Physiol Endocrinol Metab 2014, 307: E456-E461 [PMDID: 25074984 DOI: 10.1152/ajpendo.00184.2014]
9 Hoffman JR, Ratamess NA. Medical issues associated with anabolic steroid use: are they exaggerated? J Sports Sci Med 2006; 5: 182-193 [PMDID: 17321481 DOI: 10.5555/jssm.2005.4.158.4344]
10 Pope HG Jr, Wood RE, Rogel A, Nyberg F, Bowers L, Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev 2014; 35: 341-375 [PMDID: 24423981 DOI: 10.1210/er.2013-1058]
11 Solimini R, Rotolo MC, Mastrobatista L, Mortali C, Minutillo A, Pichini S, Pacifici R, Palmi I. Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping. *Eur Rev Med Pharmacol Sci* 2017; 21: 7-16 [PMID: 28379590]

12 Ruhmna CD, Crosnoe LE, Kim ED. Designer steroids - over-the-counter supplements and their androgenic component: review of an increasing problem. *Andrology* 2015; 3: 150-155 [PMID: 25868732 DOI: 10.1111/andr.307]

13 El Sherrif Y, Potts JR, Howard MR, Barnardo A, Cairns S, Kaisely AS, Verma S. Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations? *Liver Int* 2013; 33: 1266-1270 [PMID: 23758072 DOI: 10.1016/j.jlie.12216]

14 DIA: Drugs of abuse. In: Administration. United States department of justice, 2020

15 Anawalt BD. Diagnosis and Management of Anabolic Androgenic Steroid Use. *J Clin Endocrinol Metab* 2019; 104: 2490-2500 [PMID: 30753550 DOI: 10.1210/jc.2018-01882]

16 Buckman JF, Farris SG, Yusko DA. A national study of substance use behaviors among NCAA male athletes who use banned performance enhancing substances. *Drug Alcohol Depend* 2013; 131: 50-55 [PMID: 23688842 DOI: 10.1016/j.drugalcdep.2013.04.023]

17 Jenssen IH, Johannessen KB. Aggression and body image concerns among anabolic androgenic steroid users, contemplators, and controls in Norway. *Body Image* 2015; 12: 6-13 [PMID: 25261635 DOI: 10.1016/j.bodyim.2014.08.009]

18 Quaglio G, Fornasiero A, Mezzelani P, Moreschini S, Lugoboni F, Lechi A. Anabolic steroids: dependence and complications of chronic use. *Intern Emerg Med* 2009; 4: 289-296 [PMID: 19468827 DOI: 10.1007/s11739-009-0260-5]

19 Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. *Clin Ther* 2001; 23: 1355-1390 [PMID: 11589254 DOI: 10.1016/s1186-6438(01)80114-4]

20 Niedfeldt MW. Anabolic Steroid Effect on the Liver. *Curr Sports Med Rep* 2018; 17: 97-102 [PMID: 29521706 DOI: 10.1249/JSR.0000000000000467]

21 Agriesti F, Tataranni T, Pacelli C, Scrima R, Laurenzenza I, Ruggieri V, Cela O, Mazzeocci C, Salerno M, Sessa F, Sani G, Pomara C, Capitanio N, Piccoli C. Nandrolone induces a stem cell-like phenotype in human hepatocarcinoma-derived cell line inhibiting mitochondrial respiratory activity. *Sci Rep* 2020; 10: 2287 [PMID: 32041983 DOI: 10.1038/s41598-020-58771-1]

22 Sadowska-Kępa E, Klapińska B, Novara A, Jagus S, Szoltysek-Boldys I, Chalimoniu M, Langort J, Chapusta SJ. High-dose testosterone supplementation disturbs liver pro-oxidant/antioxidant balance and function in adolescent male Wistar rats undergoing moderate-intensity endurance training. *PeerJ* 2020; 8: e10228 [PMID: 33240699 DOI: 10.7717/peerj.10228]

23 Lima EM, Cassaro KODS, Silva CLD, Silva MA, Poltronieri MP, Nascimento AMD, Bisollo NS, Brasil GA. Eight weeks of treatment with nandrolone decanoate in female rats promotes disruption in the redox homeostasis and hepatic response to subchronic administration of nandrolone decanoate. *Vet Rec* 2020; 184: 861-867 [PMID: 32419635 DOI: 10.1136/vetrecr-2019-006109]

24 Gragera R, Saborido A, Molano F, Jiménez L, Muñoz F, Megías A. Ultrastructural changes induced by anabolic steroids in the rat liver. *J Invest Dermatol* 2004; 123: 1052-1056 [PMID: 15610513 DOI: 10.1111/j.0022-202X.2004.02349.x]

25 Ma X, Zhou Y, Qiao B, Jiang S, Shen Q, Han Y, Liu A, Chen X, Wei L, Zhou L, Zhao J. Androgen aggravates liver fibrosis by activation of NLRP3 inflammasome in CCl4-induced liver injury mouse model. *Am J Physiol Endocrinol Metab* 2020; 318: E817-E829 [PMID: 32182125 DOI: 10.1152/ajpendo.00427.2019]

26 Neri M, Bello S, Bonassignore A, Cantatore S, Rizzuto I, Turillazzi E, Fineschi V. Anabolic androgenic steroids abuse and liver toxicity. *Mini Rev Med Chem* 2011; 11: 430-437 [PMID: 21443508 DOI: 10.2174/138955711795445916]

27 Vieira RP, França RF, Damaceno-Rodrigues NR, Dohminkoff M, Caldini EG, Carvalho CR, Ribeiro W. Dose-dependent hepatic response to chronic administration of nandrolone decanoate. *Med Sci Sports Exerc* 2008; 40: 842-847 [PMID: 18408615 DOI: 10.1249/MSS.0b013e318166611c]

28 Schwingel PA, Cotrim HP, Salles BR, Almeida CE, dos Santos CR Jr, Nachef B, Andrade AR, Zoppo CC. Anabolic-androgenic steroids: a possible new risk factor to prostatic hypertrophy and associated fatty liver disease. *Liver Int* 2011; 31: 348-353 [PMID: 21044047 DOI: 10.1111/j.1478-3231.2010.02346.x]

29 Riezzo I, Turillazzi E, Bello S, Cantatore S, Cirrati D, Frati P, Neri M, Pedretti M, Fineschi V. Chronic nandrolone administration promotes oxidative stress, induction of pro-inflammatory cytokine and TNF-α mediated apoptosis in the kidneys of CD1 treated mice. *Toxicol Appl Pharmacol* 2014; 280: 97-106 [PMID: 25065671 DOI: 10.1016/j.taap.2014.06.031]

30 Hurtgens F, Kuipers H. Effects of anabolic-androgenic steroids in athletes. *Sports Med* 2004; 34: 513-554 [PMID: 15249778 DOI: 10.1093/sportsmed/42.6.513]

31 Dieckerman RD, Pertusi RM, Zachariah NY, Dufourt DR, McConathy WJ. Anabolic steroid-induced hepatotoxicity: is it overstated? *Clin J Sport Med* 1999; 9: 34-39 [PMID: 10365080 DOI: 10.1053/cjsm.1999.0007]

32 A Stangl T, M Wiepjes C, Defreyne J, Conenans E, D Fisher A, Schreiner T, Defreyne J, Dona A, Stefanidou M, Spiliopoulou C. Adverse effects of anabolic steroids in athletes. A constant threat. *Drug Alcohol Depend* 2005; 80: 158-175 [PMID: 16051618 DOI: 10.1016/j.drugalcdep.2005.06.005]

33 Patil V, Jothimani D, Harika K, Hakeem AR, Sachan D, Vij M, Rela M. Versatility of Anabolic Androgenic Steroid-
Induced Hepatotoxicity. *J Clin Exp Hepatol* 2022; 12: 216-221. [PMID: 35068803 DOI: 10.1016/j.jchb.2021.03.003]

Abeles RD, Foxton M, Khan S, Goldin R, Smith B, Thursz MR, Verma S. Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature. *BMJ Open Gastroenterol* 2020; 7 [PMID: 33214235 DOI: 10.1136/bmjgast-2020-000549]

Robles-Díaz M, Gonzalez-Jiménez A, Medina-Caliz I, Stephens C, García-Cortes M, García-Muñoz B, Ortega-Alonso A, Blanco-Reina E, Gonzalez-Grande R, Jimenez-Perez M, Rendon P, Navarro JM, Gines P, Prieto M, Garcia-Eliz M, Bessone F, Brahmi JR, Paraná R, Lucena MI, Andrade RJ; Spanish DILI Registry; SLatInDILI Network. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic anabolic steroids. *Aliment Pharmacol Ther* 2015; 41: 116-125. [PMID: 25394890 DOI: 10.1111/apt.13023]

Kafrouni MI, Andersen RA, Verma S. Hepatotoxicity associated with dietary supplements containing anabolic steroids. *Clin Gastroenterol Hepatol* 2007; 5: 809-812. [PMID: 17509944 DOI: 10.1016/j.cgh.2007.02.036]

Stepić PM, Reeczko K, Wieczorek A, Zarębska-Michaluk D, Papjan P, Król T, Kryczka W. Severe intrahepatic cholestasis and liver failure after stanozolol usage - case report and review of the literature. *Clin Exp Hepatol* 2015; 1: 30-33. [PMID: 2885252]. DOI: 10.5114/ceh.2015.51376

Modlinski R, Fields KB. The effect of anabolic steroids on the gastrointestinal system, kidneys, and adrenal glands. *Curr Sports Med Rep* 2006; 5: 104-109. [PMID: 16529682 DOI: 10.1097/01.csmr.0000306529.74500.fc]

Erlinger S, Arias IM, Dhumeaux D. Inherited disorders of bilirubin transport and conjugation: new insights into molecular mechanisms and consequences. *Gastroenterology* 2014; 146: 1625-1638. [PMID: 24704527 DOI: 10.1053/j.gastro.2014.03.047]

Petrov PD, Fernández-Murga L, Conde I, Martínez-Sena T, Guzmán C, Castell JV, Jover R. Epistane, an anabolic steroid used for recreational purposes, causes cholestasis with elevated levels of cholic acid conjugates, by upregulating bile acid synthesis (CYP8B1) and cross-talking with nuclear receptors in human hepatocytes. *Arch Toxicol* 2020; 94: 589-607. [PMID: 31894354 DOI: 10.1007/s00204-019-02643-9]

Chopra S, Gawrieh S, Vuppalanchi R, Saxena R. Role of the Surgical Pathologist in Diagnosis of Drug-induced Liver Injury: Recognizing Specific Patterns of Drug Injury. *Adv Anat Pathol* 2021; 28: 383-395. [PMID: 34050060 DOI: 10.1097/PAP.0000000000000307]

Goh HG, Lee YJ, Kim TH. Severe Persistent Jaundice after the Abuse of An Anabolic Androgenic Steroid Analogue. *Korean J Gastroenterol* 2020; 76: 167-170. [PMID: 32969366 DOI: 10.4166/kjg.2020.76.3.167]

Tsirigotis P, Sella T, Shapira MY, Bitan M, Bloom A, Kiselgoff D, Levin M, Libster D, Abdul Hai A, Gesundheit B, Or R, Slavin S, Resnick I. Peliosis hepatiis following treatment with androgen-steroids in patients with bone marrow failure syndromes. *Haematologica* 2007; 92: e106-e110. [PMID: 18024386 DOI: 10.3332/haematol.11343]

Tzirogiannis KN, Papadimas GK, Kondyli VG, Kourentzi KT, Demonakou MD, Hereti A, Goh HG, Foxton M, Khan S, Goldin R, Smith B, Thursz MR, Verma S. Androgenic anabolic steroid-induced liver toxicity: a comprehensive review of the literature. *Drug Alcohol Depend* 2020; 200: 101-106. DOI: 10.1016/j.drugalcdep.2019.10.029

de la Mano EP, Martin-Sánchez G, López RL, Galán MAF, Ríos ST, Jiménez MJM, de Morales JMGR, Santos MAC, Núñez GM. Peliosis hepatiis associated with oral androgen therapy. *Arch Pathol Lab Med* 2006; 130: 34050060 DOI: 10.1097/01.csmr.0000306529.74500.fc

Fidelman N, Colombo T, Greaves P. “Have you seen this? Is it peliosis?” *Gastroenterology* 2007; 35068803 DOI: 10.1053/j.gastro.2007.02.036

Choi SK, Jin JS, Cho SG, Choi SJ, Kim CS, Choe YM, Lee KY. Spontaneous liver rupture in a patient with peliosis hepatiis: a case report. *World J Gastroenterol* 2009; 15: 5493-5497. [PMID: 19916182 DOI: 10.3748/wjg.15.5493]

Nadel J, Kosek J. Peliosis hepatiis. Twelve cases associated with oral androgen therapy. *Arch Pathol Lab Med* 1977; 101: 405-410. [PMID: 577673]

Fidelman N, LaBerge JM, Kerlan RK Jr. SCVIR 2002 Film Panel case 4: massive intraperitoneal hemorrhage caused by peliosis hepatiis. *J Vasc Interv Radiol* 2002; 13: 542-545. [PMID: 11997366 DOI: 10.1016/s1051-0443(07)61539-5]

Hui CL, Lee ZJ. Hepatic disorders associated with exogenous sex steroids: MR imaging findings. *Abdom Radiol (NY)* 2019; 44: 2436-2447. [PMID: 30955069 DOI: 10.1007/s00261-019-01941-4]

Nakao A, Sakagami K, Nakata Y, Komazawa K, Amimoto T, Nakashima K, Isozaki H, Takakura N, Tanaka N. Multiple hepatic adenomas caused by long-term administration of anabolic steroids for aplastic anemia in association with familial adenomatous polyposis. *J Gastroenterol* 2000; 35: 557-562. [PMID: 10905366 DOI: 10.1007/000350700081]

Evert M, Dombrowski F. [Hepatocellular carcinoma in the non-cirrhotic liver]. *Pathologie* 2008; 29: 47-52. [PMID: 18059363 DOI: 10.1016/s0029-07-0953-3]

Sucas L, Zumbado M, Pérez-Lazaro O, Ramos A, Pérez C, Hernández JR, Boada L.D. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. *Br J Sports Med* 2005; 39: e27. [PMID: 15849280 DOI: 10.1136/bjsm.2004.013599]

Velazquez I, Alter BP. Androgens and liver tumors: Fanconis' anemia and non-Fanconis' conditions. *Am J Hematol* 2004; 77: 257-267. [PMID: 15495253 DOI: 10.1002/ajh.20183]

El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. *Gastroenterology* 2004; 127: S27-S34. [PMID: 15503084 DOI: 10.1053/j.gastro.2004.09.013]

Tanaka K, Sakai H, Hashizume M, Hirotaka T. Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. *Cancer Res* 2000; 60: 5106-5110. [PMID: 11016636]

Farges O, Ferreira N, Dokmak S, Belghiti J, Bedossa P, Paradis V. Changing trends in malignant transformation of hepatocellular adenoma. *Gut* 2011; 60: 85-89. [PMID: 21148580 DOI: 10.1136/gut.2010.222109]

European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the management of benign liver tumours. *J Hepatol* 2016; 65: 386-398. [PMID: 27085809 DOI: 10.1016/j.jhep.2016.04.001]

Aitken C, Delalande C, Stanton K. Pumping iron, risking infection? *Drug Alcohol Depend* 2002; 65: 303-308. [PMID: 11841901 DOI: 10.1016/s0376-8716(01)00174-0]
65 **Hartgens F**, Rietjens G, Keizer HA, Kuipers H, Wolffenbuttel BH. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). *Br J Sports Med* 2004; **38**: 253-259 [PMID: 15155420 DOI: 10.1136/bjsm.2003.000199]

66 **Kouri EM**, Pope HG Jr, Oliva PS. Changes in lipoprotein-lipid levels in normal men following administration of increasing doses of testosterone cypionate. *Clin J Sport Med* 1996; **6**: 152-157 [PMID: 8792045 DOI: 10.1097/00042752-199607000-00003]

67 **Magee CD**, Witte S, Kwok RM, Deuster PA. Mission Compromised? *Mil Med* 2016; **181**: e1169-e1171 [PMID: 27612377 DOI: 10.7205/MILMED-D-15-00502]

68 **Cabb E**, Baltar S, Powers DW, Mohan K, Martinez A, Pitts E. The Diagnosis and Manifestations of Liver Injury Secondary to Off-Label Androgenic Anabolic Steroid Use. *Case Rep Gastroenterol* 2016; **10**: 499-505 [PMID: 27721739 DOI: 10.1159/000448883]

69 **García-Cortés M**, Robles-Díaz M, Ortega-Alonso A, Medina-Caliz I, Andrade RJ. Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics. *Int J Mol Sci* 2016; **17**: 537 [PMID: 27070596 DOI: 10.3390/ijms17040537]

70 **Pascale B**, Steele C, Attipoe S, O’Connor FG, Deuster PA. Dietary Supplements: Knowledge and Adverse Event Reporting Among American Medical Society for Sports Medicine Physicians. *Clin J Sport Med* 2016; **26**: 139-144 [PMID: 26035683 DOI: 10.1097/JSM.0000000000000213]

71 **Medina-Caliz I**, García-Cortés M, González-Jiménez A, Cabello MR, Robles-Díaz M, Sanabria-Cabrera J, Sanjuan-Jimenez R, Ortega-Alonso A, García-Muñoz B, Moreno I, Jimenez-Perez M, Fernandez MC, Ginés P, Prieto M, Conde I, Hallal H, Soriano G, Roman E, Castiella A, Blanco-Reina E, Montes MR, Quiros-Cano M, Martin-Reyes F, Lucena MI, Andrade RJ; Spanish DILI Registry. Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. *Clin Gastroenterol Hepatol* 2018; **16**: 1495-1502 [PMID: 29307948 DOI: 10.1016/j.cgh.2017.12.051]
